Emactuzumab
As of the edition of 20 October 2026, Emactuzumab is an antibody: in active development; acts on CSF1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Antibody
- Registered trials
- 7, 2 stopped early
- Disease areas
- Cancer; Blood and lymph; Bones, joints and muscles; Hormones; Immune system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF1R | Macrophage colony-stimulating factor 1 receptor | P07333 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Roche | Lead sponsor of trials | 2011 to now |
| SynOx Therapeutics | Lead sponsor of trials | 2024 to now |